Compare FRSH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSH | IDYA |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2021 | 2019 |
| Metric | FRSH | IDYA |
|---|---|---|
| Price | $11.50 | $37.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | $19.53 | ★ $49.33 |
| AVG Volume (30 Days) | ★ 3.3M | 937.5K |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $810,640,000.00 | $214,834,000.00 |
| Revenue This Year | $18.20 | $2,662.86 |
| Revenue Next Year | $13.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.18 | ★ 5377.66 |
| 52 Week Low | $10.51 | $13.45 |
| 52 Week High | $19.77 | $39.28 |
| Indicator | FRSH | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 57.51 |
| Support Level | $11.52 | $35.94 |
| Resistance Level | $12.36 | $38.03 |
| Average True Range (ATR) | 0.34 | 1.61 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 5.50 | 65.02 |
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.